Mail

UK markets closed

FTSE 100
7,877.05
+29.06(+0.37%)
FTSE 250
19,450.67
+110.53(+0.57%)
AIM
744.99
+1.87(+0.25%)
GBP/EUR
1.1691
+0.0024(+0.20%)
GBP/USD
1.2465
+0.0009(+0.07%)
Bitcoin GBP
50,964.92
+2,454.88(+5.06%)

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

Santen Pharmaceutical Co., Ltd. (4536.T)

Tokyo - Tokyo Delayed price. Currency in JPY

Add to watchlist

1,443.00

-7.50

(-0.52%)

At close: 03:15PM JST

Currency in JPY

Valuation measures⁴

Market cap (intra-day)	526.91B
Enterprise value	443.55B
Trailing P/E	19.45
Forward P/E	N/A
PEG ratio (5-yr expected)	N/A
Price/sales (ttm)	1.78
Price/book (mrq)	1.76
Enterprise value/revenue	1.47
Enterprise value/EBITDA	7.54

Trading information

Stock price history

Beta (5Y monthly)	0.26
52-week change ³	35.43%
S&P500 52-week change ³	21.61%
52-week high ³	1,589.50
52-week low ³	1,061.00
50-day moving average ³	1,477.59
200-day moving average ³	1,389.22

Share statistics

Avg vol (3-month) ³	1.4M
Avg vol (10-day) ³	1.25M
Shares outstanding ⁵	363.26M
Implied shares outstanding ⁶	363.26M
Float ⁸	349.13M
% held by insiders ¹	2.79%
% held by institutions ¹	45.40%
Shares short ⁴	N/A
Short ratio ⁴	N/A
Short % of float ⁴	N/A
Short % of shares outstanding ⁴	N/A
Shares short (prior month ) ⁴	N/A

Dividends & splits

Forward annual dividend rate ⁴	34
Forward annual dividend yield ⁴	2.34%
Trailing annual dividend rate ³	32.00
Trailing annual dividend yield ³	2.21%
5-year average dividend yield ⁴	2.09
Payout ratio ⁴	42.91%
Dividend date ³	N/A
Ex-dividend date ⁴	28 Mar 2024
Last split factor ²	5:1
Last split date ³	27 Mar 2015

Financial highlights

Fiscal year

Fiscal year ends	31 Mar 2023
Most-recent quarter (mrq)	31 Dec 2023

Profitability

Profit margin	9.18%
Operating margin (ttm)	14.36%

Management effectiveness

Return on assets (ttm)	12.03%
Return on equity (ttm)	9.26%

Income statement

Revenue (ttm)	302.08B
Revenue per share (ttm)	815.26
Quarterly revenue growth (yoy)	8.70%
Gross profit (ttm)	N/A
EBITDA	99.33B
Net income avi to common (ttm)	27.71B
Diluted EPS (ttm)	74.56
Quarterly earnings growth (yoy)	22.70%

Balance sheet

Total cash (mrq)	83.36B
Total cash per share (mrq)	229.51
Total debt (mrq)	N/A
Total debt/equity (mrq)	N/A
Current ratio (mrq)	2.46
Book value per share (mrq)	822.49

Cash flow statement

Operating cash flow (ttm)	68.11B
Levered free cash flow (ttm)	76.02B